These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 30734242)
1. Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure. Eworuke E; Welch EC; Tobenkin A; Maro JC Drug Saf; 2019 Jul; 42(7):897-906. PubMed ID: 30734242 [TBL] [Abstract][Full Text] [Related]
2. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study. Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844 [TBL] [Abstract][Full Text] [Related]
3. Bioequivalent antiepileptic drug switching and the risk of seizure-related events. Hansen RN; Nguyen HP; Sullivan SD Epilepsy Res; 2013 Sep; 106(1-2):237-43. PubMed ID: 23726541 [TBL] [Abstract][Full Text] [Related]
4. Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. De Vecchis R; Ariano C; Giasi A; Cioppa C Minerva Cardioangiol; 2018 Jun; 66(3):349-359. PubMed ID: 28497941 [TBL] [Abstract][Full Text] [Related]
10. Ranolazine-induced lipid storage myopathy presenting with respiratory failure and head drop. Paul P; Vazquez Do Campo R; Liewluck T; Naddaf E Neuromuscul Disord; 2021 Jun; 31(6):546-550. PubMed ID: 33903020 [TBL] [Abstract][Full Text] [Related]
11. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. McAfee AT; Holdridge KC; Johannes CB; Hornbuckle K; Walker AM Curr Drug Saf; 2008 May; 3(2):123-31. PubMed ID: 18690990 [TBL] [Abstract][Full Text] [Related]
12. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. Rowhani-Rahbar A; Fireman B; Lewis E; Nordin J; Naleway A; Jacobsen SJ; Jackson LA; Tse A; Belongia EA; Hambidge SJ; Weintraub E; Baxter R; Klein NP JAMA Pediatr; 2013 Dec; 167(12):1111-7. PubMed ID: 24126936 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. Zack J; Berg J; Juan A; Pannacciulli N; Allard M; Gottwald M; Zhang H; Shao Y; Ben-Yehuda O; Jochelson P Clin Pharmacol Drug Dev; 2015 Mar; 4(2):121-9. PubMed ID: 27128216 [TBL] [Abstract][Full Text] [Related]
14. Ranolazine-Associated Myoclonus. Trehan N; Singh M; Kottam AR Am J Ther; 2018; 25(4):e507-e508. PubMed ID: 28452847 [No Abstract] [Full Text] [Related]
15. Ranolazine Induced Delirium as a Rare Side Effect. Zagelbaum NK; Mondal P; Frishman WH; Yandrapalli S Am J Ther; 2018; 25(6):e700-e701. PubMed ID: 30010629 [No Abstract] [Full Text] [Related]
17. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: A systematic review with meta-analysis. Brigo F; Nardone R; Tezzon F; Trinka E Epilepsy Behav; 2015 Aug; 49():325-36. PubMed ID: 25817929 [TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions. Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510 [TBL] [Abstract][Full Text] [Related]
19. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Jerling M; Abdallah H Clin Pharmacol Ther; 2005 Sep; 78(3):288-97. PubMed ID: 16153399 [TBL] [Abstract][Full Text] [Related]